Avaleht › Ülekaalulisus › Utah
Ülekaalulisus kliinilised uuringud osariigis Utah
22 uuringut haiguse Ülekaalulisus jaoks otsivad osalejaid osariigis Utah.
Linnad osariigis Utah
Ametlik uuringutekst (inglise keeles)
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
- AMR Clinical, Layton
VärbamineFaas 3
Vanused 8–18 · Kõik sood · Uuendatud 30. sept 2026 · NCT07253285Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss
- AMR Clinical, South Jordan
VärbamineFaas 2
Vanused 18–75 · Kõik sood · Uuendatud 28. sept 2026 · NCT07837973A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
- Velocity Clinical Research, Salt Lake City, West Jordan
VärbamineFaas 3
Vanused 6–17 · Kõik sood · Uuendatud 24. sept 2026 · NCT06672549A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
- Ogden Clinic - Canyon View, Ogden
- Diabetes & Endocrine Treatment Specialists, Sandy City
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 22. sept 2026 · NCT07282600Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- Boeson Research, Provo
- Velocity Clinical Research - Salt Lake City, West Jordan
VärbamineFaas 3
Vanused 45–99 · Kõik sood · Uuendatud 22. sept 2026 · NCT07037433Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
- AMR Clinical, South Jordan
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 22. sept 2026 · NCT07353931A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
- AURORA-1 Clinical Site, Salt Lake City
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 16. sept 2026 · NCT07743463A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, Salt Lake City
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 16. sept 2026 · NCT07743450A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
- George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 14. sept 2026 · NCT07351045A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
- ACCOMPLISH-2 Research Site, Salt Lake City
VärbamineFaas 3Terved vabatahtlikud oodatud
Vanused 18–79 · Kõik sood · Uuendatud 11. sept 2026 · NCT07654374A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
- Kalo Clinical Research, West Valley City
VärbamineFaas 2
Vanused 18–75 · Kõik sood · Uuendatud 8. sept 2026 · NCT07215559A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
- Tanner Clinic, Layton
VärbamineFaas 4
Vanused 18 ja vanemad · Kõik sood · Uuendatud 4. sept 2026 · NCT06857942Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
- Kailera Clinical Site, Pleasant View
- Kailera Clinical Site, Salt Lake City
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 3. sept 2026 · NCT07284901Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
- Pantheon Clinical Research, Bountiful
- Alliance for Multispecialty Research Layton Research Center, Layton
- Chrysalis Clinical Research, LLC, St. George
VärbamineFaas 3
Vanused 18–99 · Kõik sood · Uuendatud 3. sept 2026 · NCT07684235Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
- Kailera Clinical Site, Salt Lake City
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 3. sept 2026 · NCT07284875A Study of LY4174794 in Participants With Obesity or Overweight Who Are Otherwise Healthy
- ICON Early Phase Services, LLC, Salt Lake City
VärbamineFaas 1Terved vabatahtlikud oodatud
Vanused 18–65 · Kõik sood · Uuendatud 1. sept 2026 · NCT07654972A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
- Research Site, Salt Lake City
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 25. aug 2026 · NCT07784725Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
- ACCOMPLISH-1 Research Site, Sandy City
- ACCOMPLISH-1 Research Site, St. George
VärbamineFaas 3
Vanused 18–79 · Kõik sood · Uuendatud 10. aug 2026 · NCT07654361Circadian Intervention to Improve Cardiometabolic Health
- College of Health Research Complex--University of Utah, Salt Lake City
VärbamineTerved vabatahtlikud oodatud
Vanused 18–45 · Kõik sood · Uuendatud 5. aug 2026 · NCT05943626Effect of Sleep Extension on Ceramides in People With Overweight and Obesity
- College of Health Research Complex--University of Utah, Salt Lake City
VärbamineTerved vabatahtlikud oodatud
Vanused 18–45 · Kõik sood · Uuendatud 5. aug 2026 · NCT06180837Testing a Tailored Approach to Long-Term Weight Loss Success
- University of Utah, Salt Lake City
VärbamineTerved vabatahtlikud oodatud
Vanused 18–65 · Kõik sood · Uuendatud 11. mai 2026 · NCT07577765The Acute T-Rex (Timing of Resistance Exercise) Study
- University of Utah HPER E Buildling, Salt Lake City
Värbamine
Vanused 50–74 · Kõik sood · Uuendatud 3. apr 2025 · NCT06366399Allikas ClinicalTrials.gov, andmed saadud 5. okt 2026. Igal uuringul on oma osalemiskõlblikkuse tingimused; uuringumeeskond otsustab, kes saab osaleda.